Antiangiogenic activity of Elaiophylin via downregulation of VEGFR2 and HIF-1α

World Cancer Summit 2018

July 02-03, 2018 Bangkok, Thailand

Haet Nim Lim and Hye Jin Jung

Sun Moon University, South Korea

Posters & Accepted Abstracts: J Cancer Sci Ther

Abstract :

Cancer is an angiogenesis-dependent disease and angiogenesis inhibition is one of the important strategy to arrest tumor growth and metastasis. The current study demonstrated that a microbial metabolite, elaiophylin, exhibits potent antiangiogenic activity from in vitro and in vivo angiogenesis assays. Elaiophylin dramatically suppressed in vitro angiogenic characteristics such as proliferation, migration, adhesion, invasion and tube formation of Human Umbilical Vein Endothelial Cells (HUVECs) stimulated by Vascular Endothelial Growth Factor (VEGF) at non-toxic concentrations. In addition, elaiophylin immensely inhibited in vivo angiogenesis of the Chorioallantoic Membrane (CAM) from growing chick embryos without cytotoxicity. The activation of VEGF receptor 2 (VEGFR2) in HUVECs by VEGF was inhibited by elaiophylin, resulting in the suppression of VEGF-induced activation of downstream signaling molecules, Akt, extracellular signal-regulated kinase 1/2 (ERK1/2), c-Jun N-terminal Kinase (JNK), p38, Nuclear Factor-�ºB (NF�ºB), Matrix Metalloproteinase (MMP)-2 and -9. We also found that elaiophylin blocked tumor cell-induced angiogenesis both in vitro and in vivo. Elaiophylin downregulated the expression of VEGF by inhibiting Hypoxia Inducible Factor-1�º (HIF-1�º) accumulation in tumor cells. Therefore, elaiophylin could be utilized as a new class of natural antiangiogenic agent for cancer therapy.

Biography :

Haet Nim Lim has obtained her Bachelor’s degree in Pharmaceutical Engineering from Sun Moon University, South Korea in 2015. Currently, she is pursuing her Masters in Life Science and Biochemical Engineering in Sun Moon University, South Korea.

E-mail: gotsla9210@naver.com